Published in Clin Chem on August 24, 2006
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol (2009) 1.65
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol (2010) 1.19
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One (2008) 1.13
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med (2007) 1.13
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology (2015) 1.10
Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol (2014) 1.06
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One (2008) 1.05
Assessing liver fibrosis with serum marker models. Clin Biochem Rev (2007) 1.02
Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One (2014) 1.02
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep (2011) 1.01
Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) (2011) 0.95
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One (2012) 0.94
Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol (2010) 0.93
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am (2011) 0.91
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. BMC Gastroenterol (2012) 0.91
Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Br J Gen Pract (2012) 0.90
Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol (2007) 0.90
Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol (2013) 0.89
Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol (2008) 0.87
Non-invasive diagnosis of hepatitis B virus-related cirrhosis. World J Gastroenterol (2014) 0.87
Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One (2013) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol (2012) 0.85
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol (2009) 0.84
The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther (2013) 0.82
Automated morphometry provides accurate and reproducible virtual staging of liver fibrosis in chronic hepatitis C. J Pathol Inform (2015) 0.81
Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2014) 0.79
Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep (2014) 0.79
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clin J Am Soc Nephrol (2017) 0.79
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med (2012) 0.78
Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. J Gastroenterol Hepatol (2016) 0.77
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS One (2015) 0.77
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2011) 0.76
Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI. World J Hepatol (2014) 0.75
Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia. World J Gastroenterol (2015) 0.75
Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease. Dig Dis Sci (2015) 0.75
Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol (2012) 0.75
Rheumatic manifestations of hepatitis B and C and their association with viral load and fibrosis of the liver. Rheumatol Int (2009) 0.75
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Viral hepatitis C. Lancet (2003) 5.81
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Viral hepatitis B. Lancet (2003) 4.86
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Truth survival in clinical research: an evidence-based requiem? Ann Intern Med (2002) 2.87
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest (2012) 2.62
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood (2003) 2.53
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2010) 2.13
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology (2009) 2.10
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol (2003) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology (2004) 2.01
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84